Jubilant Pharmova Ltd Financials
Company Logo

Jubilant Pharmova Ltd Financial Statement

Jubilant Pharmova Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue209.50
Operating Expense171.80
Net Profit10.50
Net Profit Margin5.01
Earning Per Share0.66
EBIDTA36.90
Effective Tax Rate14.06

Jubilant Pharmova Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual784.70
Operating Expenses Annual768.20
Operating Profit Annual119.90
Interest Annual29.90
Depreciation36.60
Net Profit Annual31.60
Tax Annual10.10

Jubilant Pharmova Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning11
Cash Flow from Operations143.20
Cash Flow from Investing-40.30
Cash Flow from Financing-77.80
Cash Flow at the End36.10

Jubilant Pharmova Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.28
PBIT Margin (%)9.12
PBT Margin (%)8.82
Net PROFIT Margin (%)4.03
Return On Networth / Equity (%)1.32
Return On Networth /Employed (%)2.57
Return On Assets (%)1.13
Total Debt / Equity (X)0.15
Asset Turnover Ratio (%)0.28

Jubilant Pharmova Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual711.30
Total Current Assets Annual540.60
Non Current Assets Annual2,451.30
Total Shareholders Funds Annual2,374.50
Total Assets Annual2,991.90

Jubilant Pharmova Ltd Earning Calls

EPS (INR)

Expected

6.51

Reported

6.47

Surprise

-0.61%

Jun 2024

EPS beaten by -0.61%

Mar 2024

EPS beaten by -0.23%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Jubilant Pharmova Ltd has a market capitalization of 9,056.21 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Jubilant Pharmova Ltd is debt-free with a debt-to-equity ratio of 0.16.
In FY 2023 , Jubilant Pharmova Ltd recorded a total revenue of approximately 755.20 Cr marking a significant milestone in the company's financial performance.
Jubilant Pharmova Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.0% annually, respectively..
Jubilant Pharmova Ltd's current PE ratio is 286.59.
Jubilant Pharmova Ltd's ROCE averaged 3.3% from the FY ending March 2022 to 2024, with a median of 3.5%. It peaked at 3.6% in March 2022, reflecting strong capital efficiency over the period..
Jubilant Pharmova Ltd's latest EBIT is Rs. 71.60 Cr, surpassing the average EBIT of Rs. 88.37 Cr over the 5 years..